TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04300881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Following intravitreal ocriplasmin therapy
Study: NCT04513405

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: a peripheral venous blood sample will be analyzed to measure the levels of estrone and estradiol.~The sample of the blood sample will be deposited in the red cap tube with a polymeric gel.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: a peripheral venous blood sample will be analyzed to measure the levels of estrone and estradiol.~The sample of the blood sample will be deposited in the red cap tube with a polymeric gel.
Study: NCT01337232

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Complex sentence treatment protocol
Description: Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex sentence treatment protocol
Description: Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
Study: NCT04315909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP-Fibrin Glue
Description: Platelet-Rich Plasma-Fibrin Glue
Study: NCT02578030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465 12.5mg
Study: NCT04513405

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Shave Biopsy
Description: in the tissues, of the related estrogenic receptors, estrogen α receptors, estrogen β receptors (ER- α, ER-β) and G protein-coupled estrogen receptor 1 (GPER) correlates with the functional status of these receptors

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Shave Biopsy
Description: in the tissues, of the related estrogenic receptors, estrogen α receptors, estrogen β receptors (ER- α, ER-β) and G protein-coupled estrogen receptor 1 (GPER) correlates with the functional status of these receptors
Study: NCT03183960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor
Description: Traditional rehabilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mentor
Description: Traditional rehabilitation.
Study: NCT04546867

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sonographic based visualization of a pancreatic stent
Description: As described above. All patients start with an ultasound-based approach to visualize pancreatic stents position. Depending on the findings, x-ray will be performed if no stent is visualized in the pancreatic duct or an esophagogastroduodenoscopy will be performed to remove the pancreatic stent and confirm sonographic findings if the pancreatic stent is displayed in situ.
Study: NCT00674375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic risk alerts
Description: Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
Study: NCT02805062

Intervention type: PROCEDURE
Intervention: Digital Pleural Manometry
Description: Measurement of intra-pleural pressure and the removal of pleural fluid.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Subject lies a long tunnel shaped scanner and images are recorded.
Study: NCT01095666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Placebo
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Placebo
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Placebo
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks
Study: NCT02578030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465 25mg
Study: NCT01095666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
Study: NCT02947347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib 560mg administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to match ibrutinib
Description: placebo capsules to match ibrutinib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab 375mg/m\^2 IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab
Description: rituximab 375mg/m\^2 IV
Study: NCT01687244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSTILADRIN
Description: The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
Study: NCT04315909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP-Fibrin Glue
Description: Platelet-Rich Plasma-Fibrin Glue

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E and C
Description: Vitamin E and vitamin C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01105728

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic resection
Description: Endoscopic resection of the gastric subepithelial mass
Study: NCT04367428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of probiotics
Description: Patients will receive the previously mentioned combination of probiotics before and after surgery
Study: NCT03798405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Analgesic Inpatient Narcotic-Sparing
Description: Medications suggested to the physician with enhanced ease of ordering.
Study: NCT04356391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Graft Technique
Description: For the sites receiving the control technique (Connective Tissue Graft), the technique described by Langer B. and Langer L. will be started with a sulcular incision followed by a partial thickness flap. A CTG is then harvested according to the technique described by Bruno, the first incision is perpendicular to the 2nd premolar and 1st molar and is 2-3mm apical to their gingival margin as wide as the recipient site, followed by a second incision parallel to the for mentioned teeth, 1-2mm apical to the first incision, then the CTG is raised by periosteal elevator and released from apical and lateral attachments by sharp incision when needed. The graft is then prepared to have a homogenous thickness of 1.5-2mm. The donor CTG is stabilized to the underlying connective tissue interproximally using 4-0 Vicryl sutures. The recipient flap is repositioned coronally, to cover as much as possible of the graft with no tension, 2mm coronal to the CEJ, then sutured with 4-0 Vicryl sutures.
Study: NCT03383614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSF emodepside (BAY 44-4400) or matching placebo
Description: Emodepside administered as an LSF oral solution (1mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSF emodepside (BAY 44-4400) or matching placebo
Description: Emodepside administered as an LSF oral solution (1mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSF emodepside (BAY 44-4400) or matching placebo
Description: Emodepside administered as an LSF oral solution (1mg/mL)
Study: NCT02447640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX48621
Description: ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX48621
Description: ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]FPEB
Description: radiotracer used for PET scanning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]FPEB
Description: radiotracer used for PET scanning
Study: NCT03623022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinical Center Reference Endotoxin (CCRE)
Description: subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinical Center Reference Endotoxin (CCRE)
Description: subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
Study: NCT05146934

Intervention type: RADIATION
Intervention: high resolution CT
Description: Ground glass，honeycomb，reticulation, consolidation

Intervention type: RADIATION
Intervention: high resolution CT
Description: Ground glass，honeycomb，reticulation, consolidation
Study: NCT01459887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP combined with CMAB304
Description: Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP, CMAB304
Description: First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
Study: NCT02293590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab Pegol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Study: NCT03595449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine jelly
Description: lidocaine 2% jelly applied during Mohs surgery

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Surgilube
Description: surgilube (placebo) applied during Mohs surgery
Study: NCT02754661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COLON Capsule endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomographic Colonography
Study: NCT03253133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 \* 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~\* Start level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU or Folfiri
Description: Association of chemotherapy by LV5FU or Folfiri according pratician choice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone
Study: NCT00201760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV over 30 minutes on Days 1 and 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 IV over 30 minutes on Days 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30 mg/m2 IV on Day 1 and Day 8.
Study: NCT00500812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin
Study: NCT03964506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
Study: NCT01871272

Intervention type: PROCEDURE
Intervention: Arthroscopic Meniscus Surgery
Description: Surgery to the meniscus - resection or repair.
Study: NCT03032250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Attend interventionist sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch video
Description: Watch video on a DVD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch video
Description: Watch video on a DVD
Study: NCT01265810

Intervention type: OTHER
Group type: OTHER
Intervention: supersaturated calcium-phosphate
Description: 4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)

Intervention type: OTHER
Group type: OTHER
Intervention: supersaturated calcium-phosphate
Description: 4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)

Intervention type: OTHER
Group type: OTHER
Intervention: sodium chloride 0.9 %
Description: 4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)

Intervention type: OTHER
Group type: OTHER
Intervention: sodium chloride 0.9 %
Description: 4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
Study: NCT03032250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Module completion of the Prepare to Care kit
Description: Complete modules of the Prepare to Care kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Module completion of the Prepare to Care kit
Description: Complete modules of the Prepare to Care kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salivary cortisol collection
Description: Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salivary cortisol collection
Description: Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
Study: NCT00014170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT01614912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496
Description: 40 or 80 mg once daily orally
Study: NCT00254163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Study: NCT04356391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pinhole Surgical Technique
Description: For the sites receiving the test technique (Chao Pinhole Surgical Technique) the surgery starts with a small pinhole opening in the alveolar mucosa apical to the mucogingival junction of the affected tooth, the flap is then undermined using special instruments to create a full thickness pouch, followed by extending the pouch horizontally and coronally to undermined the adjacent papilla without incising it and free the flap for its coronal displacement. Then multiple 2x12mm strips of collagen resorbable membrane material (Bio-Gide, Geistlich Pharma AG) are packed under the papilla to secure the flap in a coronal direction. Gentle pressure is applied for 5 minutes to minimize the thickness of the blood clot after each of the procedures. The patients are advised to brush all teeth and sites except the buccal surfaces of the operated-on teeth, which are to be cleaned with 0.12% Chlorhexidine mouth rinse.
Study: NCT02256020

Intervention type: OTHER
Group type: OTHER
Intervention: Original lifestyle
Description: Control group with 3 times of watching 50-minute television a week for 6 months.
Study: NCT01209975

Intervention type: PROCEDURE
Intervention: Selective Laser Trabeculoplasty
Description: Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
Study: NCT01920971

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: infrared therapy
Description: wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: infrared therapy
Description: wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
Study: NCT02536157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoplastic splinting

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoplastic splinting
Study: NCT01913171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT01574261

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inositol
Description: Inositol 4g/die for four months
Study: NCT02099760

Intervention type: DEVICE
Intervention: STD testing (GC/Ct/trich)
Study: NCT03132441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training for Frailty
Description: Cardiac Rehabilitation, abbreviated course
Study: NCT01562678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
Study: NCT00786097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINLYN (Lactic Acid)
Study: NCT02070341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol
Study: NCT02256020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheel-chair music aerobic exercise (WC-MAE)
Description: Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
Study: NCT02070341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picosalax
Study: NCT02406716

Intervention type: OTHER
Intervention: Biospecimen retention

Intervention type: OTHER
Intervention: Biospecimen retention
Study: NCT02033655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: \> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling and group education lessons
Description: Participants meet once a week for 6 months to participate in group lessons and counseling.
Study: NCT03288129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: film-coated tablets